Near-Infrared Responsive Nanoplatform for Synergistic Photothermal Therapy/Chemotherapy of Lung Cancer
Source abstract
Abstract
Lung cancer is one of the most prevalent and lethal solid tumors worldwide. Traditional treatment methods mainly rely on chemotherapeutic drugs, which kill tumor cells by inhibiting their mitosis and proliferation. However, in clinical practice, first-line chemotherapeutic agents often exhibit short half-lives and induce a range of adverse reactions while potentially leading to tumor cell resistance, significantly reducing therapeutic efficacy. To address these issues, we developed a novel nanoplatform (TSPD), which used titanium dioxide (TiO 2 ) as a core template to fabricate porous silica-coated nanoparticles (TiO 2 @SiO 2 ), further coated with the photothermal agent polydopamine (PDA) and loaded with docetaxel (DTX). Once internalized by tumor cells, TSPD rapidly released DTX under the acidic conditions of the endosomes, effectively inhibiting tumor cell proliferation. Upon near-infrared (NIR) irradiation, TSPD induced localized hyperthermia, which not only promoted tumor cell death but also accelerated the release of DTX. Furthermore, TSPD exhibited a prolonged tumor retention in vivo, markedly increasing drug retention time at the tumor site, thus enhancing the therapeutic effect. This study provides a promising strategy for the development of novel nanomedicines in the synergistic application of photothermal therapy (PTT) and chemotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Photoacoustic and Ultrasonic Imaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Thoracic Surgery, The Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
Department of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
Funding
Beijing Medical and Health Foundation
References (38)
Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
3. 10.1038/s41568-018-0038-z10.1038/s41568-018-0038-z ↗
4. 10.1038/nrc.2018.1510.1038/nrc.2018.15 ↗
5. 10.1158/0008-5472.CAN-16-153610.1158/0008-5472.CAN-16-1536 ↗
6. 10.1021/acsami.4c0776010.1021/acsami.4c07760 ↗
7. 10.1186/s12951-021-01085-y10.1186/s12951-021-01085-y ↗
8. 10.1155/2015/69091610.1155/2015/690916 ↗
9. 10.2147/CMAR.S4060110.2147/CMAR.S40601 ↗
10. 10.1016/j.colsurfb.2014.06.05910.1016/j.colsurfb.2014.06.059 ↗
11. 10.1007/s12325-018-0707-z10.1007/s12325-018-0707-z ↗
12. 10.1016/j.drup.2014.04.00110.1016/j.drup.2014.04.001 ↗
13. 10.1016/j.jconrel.2019.12.01710.1016/j.jconrel.2019.12.017 ↗
14. 10.1016/j.biomaterials.2016.03.03210.1016/j.biomaterials.2016.03.032 ↗
15. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
16. 10.1039/D0CS00664E10.1039/D0CS00664E ↗
17. 10.1016/j.biomaterials.2020.12034610.1016/j.biomaterials.2020.120346 ↗
18. 10.1002/adma.20210257010.1002/adma.202102570 ↗
19. 10.1016/j.biomaterials.2021.12079210.1016/j.biomaterials.2021.120792 ↗
20. 10.1016/j.biomaterials.2014.06.01310.1016/j.biomaterials.2014.06.013 ↗
21. 10.1002/adma.20220565310.1002/adma.202205653 ↗
22. 10.1002/smtd.20237002510.1002/smtd.202370025 ↗
23. 10.1039/C4NR00708E10.1039/C4NR00708E ↗
24. 10.1021/acs.nanolett.2c0339210.1021/acs.nanolett.2c03392 ↗
25. 10.1002/anie.20160524110.1002/anie.201605241 ↗
26. 10.1038/ncomms1043710.1038/ncomms10437 ↗
27. 10.1002/smll.20230354110.1002/smll.202303541 ↗
28. 10.1517/17425247.2013.75863110.1517/17425247.2013.758631 ↗
29. 10.1016/j.nano.2013.04.00210.1016/j.nano.2013.04.002 ↗
30. 10.1016/j.biomaterials.2016.08.03910.1016/j.biomaterials.2016.08.039 ↗
31. 10.1016/j.biomaterials.2022.12142510.1016/j.biomaterials.2022.121425 ↗
32. 10.1002/anbr.20230009410.1002/anbr.202300094 ↗
33. Li Y Zhang Y Dong Y Akakuru OU Yao X Yi J Li X Wang L Lou X Zhu B et al. Ablation of gap junction protein improves the efficiency of nanozyme-mediated catalytic/starvation/mild-temperature photothermal therapy. Adv Mater. 2023;35(22):2210464.10.1002/adma.202210464 ↗
34. 10.1002/EXP.2022016110.1002/EXP.20220161 ↗
35. 10.1021/acs.nanolett.4c0562510.1021/acs.nanolett.4c05625 ↗
36. 10.1016/j.colsurfb.2021.11159610.1016/j.colsurfb.2021.111596 ↗
37. 10.1016/j.mtbio.2024.10105210.1016/j.mtbio.2024.101052 ↗
38. 10.1002/advs.20220173410.1002/advs.202201734 ↗